Latest Data on ALK-Positive Advanced NSCLC

Join our distinguished panel of experts, Drs Yasir Elamin and Kaushal Parikh, for an engaging discussion on recent key data on ALK-positive advanced NSCLC. This session, which includes expert commentary on clinical implications from oral and poster presentations at ASCO, ESMO, and WCLC 2023, focuses on the use of circulating tumor DNA (ctDNA), the combination of local consolidative therapy with an ALK-TKI (i.e., the BRIGHTSTAR study)and the impact of quality of life on treatment decisions in patients with ALK-positive advanced NSCLC.

Medscape © 2024 WebMD Medical Affairs Services, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Supported by Takeda Oncology Medical Affairs. Takeda provided input on the topic choice and funding support to produce content. Content was reviewed for scientific accuracy by Takeda Medical colleagues. Views expressed by faculty are their own.

Cite this: Spotlight on ALK-Positive Advanced NSCLC: Examining the Latest Data  - Medscape - May 02, 2024.